Could red light help breast cancer survivors regrow hair after chemo?
NCT ID NCT07594678
First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times
Summary
This study tests whether adding low-level red-light therapy to the standard hair-loss treatment minoxidil helps breast cancer patients regrow hair lost during chemotherapy. About 50 adults with stage I-IV breast cancer who lost at least half their scalp hair after chemo will be enrolled. Researchers will compare hair regrowth at 6 months using a standard scale.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients will be Ohio State University patients \> 18 years old * Patients will have a diagnosis of breast cancer, stages I-IV * Patients will have been treated with a chemotherapy regimen containing either an anthracycline or taxane * Patients will have a loss of at least 50% of the hair on the scalp by the final chemotherapy infusion * Patients will NOT be pregnant or nursing women * Patients will NOT have a history of scarring/cicatricial alopecia or alopecia areata * Patients will NOT have a known sensitivity to minoxidil * Patients will NOT have ongoing treatment with an antibody-drug conjugate or immunotherapy * NOTE: There is no exclusion criteria for utilization of scalp cooling
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anatomic stage I breast cancer ajcc V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug cocktail make immunotherapy work better for Hard-to-Treat breast cancer?
- Can a Weight-Loss drug shield breast cancer Survivors' hearts?
- Vitamin d gel on the scalp: a new hope against chemo hair loss?
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Digital therapy aims to tame the fear that haunts cancer survivors